Matica Bio zeroes in on bridging global biotech with Korea

Matica Biotechnology is positioning Korea as a strategic destination for investigator-initiated trials, or IITs, by offering an integrated platform that combines manufacturing, clinical development and regulatory support. The move comes as global drugmakers are diversifying manufacturing and clinical development away from China amid rising geopolitical tensions. According to Matica Biotechnology — the US-based contract development and manufacturing subsidiary of Korea’s Cha Biotech — on Sunday,

By The Korea Herald